Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Cancer Tubulin Inhibitors market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Cancer Tubulin Inhibitorsmarket, defines the market attractiveness level of Cancer Tubulin Inhibitors market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Cancer Tubulin Inhibitors industry, describes the types of Cancer Tubulin Inhibitors market, the applications of major players and the market size, and deeply analyzes the current situation of the global Cancer Tubulin Inhibitors market and the development prospects and opportunities of Cancer Tubulin Inhibitors industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Cancer Tubulin Inhibitors market in Chapter 13.
By Player:
Roche
Genentech
Immunogen
Seattle Genetics
Modra Pharmaceuticals
Agensys
Celgene
Abraxis Biosciences
Amgen
Tocris Bioscience
Sanofi-Aventis
Endocyte
Eagle Pharmaceuticals
Pierre Fabre
By Type:
Docetaxel
Trastuzumab Emtansine
Abraxane
Brentuximab Vedotin
Cabazitaxel
By End-User:
Non Small Cell Lung Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Ovarian Cancer
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Cancer Tubulin Inhibitors Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Cancer Tubulin Inhibitors Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Cancer Tubulin Inhibitors Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Cancer Tubulin Inhibitors Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Cancer Tubulin Inhibitors Market Analysis and Outlook to 2022
-
7.1 Global Cancer Tubulin Inhibitors Consumption (2017-2022)
-
7.2 United States Cancer Tubulin Inhibitors Consumption (2017-2022)
-
7.3 Europe Cancer Tubulin Inhibitors Consumption (2017-2022)
-
7.4 China Cancer Tubulin Inhibitors Consumption (2017-2022)
-
7.5 Japan Cancer Tubulin Inhibitors Consumption (2017-2022)
-
7.6 India Cancer Tubulin Inhibitors Consumption (2017-2022)
-
7.7 South Korea Cancer Tubulin Inhibitors Consumption (2017-2022)
8 Region and Country-wise Cancer Tubulin Inhibitors Market Analysis and Outlook to 2028
-
8.1 Global Cancer Tubulin Inhibitors Consumption Forecast (2022-2028)
-
8.2 United States Cancer Tubulin Inhibitors Consumption Forecast (2022-2028)
-
8.3 Europe Cancer Tubulin Inhibitors Consumption Forecast (2022-2028)
-
8.4 China Cancer Tubulin Inhibitors Consumption Forecast (2022-2028)
-
8.5 Japan Cancer Tubulin Inhibitors Consumption Forecast (2022-2028)
-
8.6 India Cancer Tubulin Inhibitors Consumption Forecast (2022-2028)
-
8.7 South Korea Cancer Tubulin Inhibitors Consumption Forecast (2022-2028)
9 Global Cancer Tubulin Inhibitors Market Outlook by Types and Applications to 2022
-
9.1 Global Cancer Tubulin Inhibitors Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Docetaxel Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Trastuzumab Emtansine Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Abraxane Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Brentuximab Vedotin Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Cabazitaxel Consumption and Growth Rate (2017-2022)
-
9.2 Global Cancer Tubulin Inhibitors Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Non Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Prostate Cancer Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Breast Cancer Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Colorectal Cancer Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Ovarian Cancer Consumption and Growth Rate (2017-2022)
10 Global Cancer Tubulin Inhibitors Market Outlook by Types and Applications to 2028
-
10.1 Global Cancer Tubulin Inhibitors Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Docetaxel Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Trastuzumab Emtansine Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Abraxane Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Brentuximab Vedotin Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Cabazitaxel Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Cancer Tubulin Inhibitors Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Non Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Prostate Cancer Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Colorectal Cancer Consumption Forecast and Growth Rate (2022-2028)
-
10.2.5 Global Ovarian Cancer Consumption Forecast and Growth Rate (2022-2028)
11 Global Cancer Tubulin Inhibitors Import and Export Analysis (Top 5 Countries)
-
11.1 Global Cancer Tubulin Inhibitors Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Cancer Tubulin Inhibitors Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Cancer Tubulin Inhibitors Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Cancer Tubulin Inhibitors Market Competitive Analysis
-
14.1 Roche
-
14.1.1 Roche Company Details
-
14.1.2 Roche Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Roche Cancer Tubulin Inhibitors Product and Service
-
14.2 Genentech
-
14.2.1 Genentech Company Details
-
14.2.2 Genentech Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Genentech Cancer Tubulin Inhibitors Product and Service
-
14.3 Immunogen
-
14.3.1 Immunogen Company Details
-
14.3.2 Immunogen Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Immunogen Cancer Tubulin Inhibitors Product and Service
-
14.4 Seattle Genetics
-
14.4.1 Seattle Genetics Company Details
-
14.4.2 Seattle Genetics Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Seattle Genetics Cancer Tubulin Inhibitors Product and Service
-
14.5 Modra Pharmaceuticals
-
14.5.1 Modra Pharmaceuticals Company Details
-
14.5.2 Modra Pharmaceuticals Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Modra Pharmaceuticals Cancer Tubulin Inhibitors Product and Service
-
14.6 Agensys
-
14.6.1 Agensys Company Details
-
14.6.2 Agensys Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Agensys Cancer Tubulin Inhibitors Product and Service
-
14.7 Celgene
-
14.7.1 Celgene Company Details
-
14.7.2 Celgene Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Celgene Cancer Tubulin Inhibitors Product and Service
-
14.8 Abraxis Biosciences
-
14.8.1 Abraxis Biosciences Company Details
-
14.8.2 Abraxis Biosciences Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Abraxis Biosciences Cancer Tubulin Inhibitors Product and Service
-
14.9 Amgen
-
14.9.1 Amgen Company Details
-
14.9.2 Amgen Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Amgen Cancer Tubulin Inhibitors Product and Service
-
14.10 Tocris Bioscience
-
14.10.1 Tocris Bioscience Company Details
-
14.10.2 Tocris Bioscience Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Tocris Bioscience Cancer Tubulin Inhibitors Product and Service
-
14.11 Sanofi-Aventis
-
14.11.1 Sanofi-Aventis Company Details
-
14.11.2 Sanofi-Aventis Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Sanofi-Aventis Cancer Tubulin Inhibitors Product and Service
-
14.12 Endocyte
-
14.12.1 Endocyte Company Details
-
14.12.2 Endocyte Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.12.3 Endocyte Cancer Tubulin Inhibitors Product and Service
-
14.13 Eagle Pharmaceuticals
-
14.13.1 Eagle Pharmaceuticals Company Details
-
14.13.2 Eagle Pharmaceuticals Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.13.3 Eagle Pharmaceuticals Cancer Tubulin Inhibitors Product and Service
-
14.14 Pierre Fabre
-
14.14.1 Pierre Fabre Company Details
-
14.14.2 Pierre Fabre Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.14.3 Pierre Fabre Cancer Tubulin Inhibitors Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Cancer Tubulin Inhibitors
-
Figure Cancer Tubulin Inhibitors Picture
-
Table Global Cancer Tubulin Inhibitors Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Cancer Tubulin Inhibitors Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Cancer Tubulin Inhibitors Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Cancer Tubulin Inhibitors Consumption by Country (2017-2022)
-
Figure United States Cancer Tubulin Inhibitors Consumption and Growth Rate (2017-2022)
-
Table Europe Cancer Tubulin Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure China Cancer Tubulin Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Japan Cancer Tubulin Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure India Cancer Tubulin Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure South Korea Cancer Tubulin Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Cancer Tubulin Inhibitors Consumption Forecast by Country (2022-2028)
-
Figure United States Cancer Tubulin Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Cancer Tubulin Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Cancer Tubulin Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Cancer Tubulin Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Cancer Tubulin Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Cancer Tubulin Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Docetaxel Consumption and Growth Rate (2017-2022)
-
Figure Global Trastuzumab Emtansine Consumption and Growth Rate (2017-2022)
-
Figure Global Abraxane Consumption and Growth Rate (2017-2022)
-
Figure Global Brentuximab Vedotin Consumption and Growth Rate (2017-2022)
-
Figure Global Cabazitaxel Consumption and Growth Rate (2017-2022)
-
Figure Global Non Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Prostate Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Colorectal Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Ovarian Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Docetaxel Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Trastuzumab Emtansine Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Abraxane Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Brentuximab Vedotin Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Cabazitaxel Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Non Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Prostate Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Colorectal Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ovarian Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Cancer Tubulin Inhibitors Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Cancer Tubulin Inhibitors Export by Region (Top 5 Countries) (2017-2028)
-
Table Roche (Foundation Year, Company Profile and etc.)
-
Table Roche Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Cancer Tubulin Inhibitors Product and Service
-
Table Genentech (Foundation Year, Company Profile and etc.)
-
Table Genentech Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genentech Cancer Tubulin Inhibitors Product and Service
-
Table Immunogen (Foundation Year, Company Profile and etc.)
-
Table Immunogen Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Immunogen Cancer Tubulin Inhibitors Product and Service
-
Table Seattle Genetics (Foundation Year, Company Profile and etc.)
-
Table Seattle Genetics Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Seattle Genetics Cancer Tubulin Inhibitors Product and Service
-
Table Modra Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Modra Pharmaceuticals Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Modra Pharmaceuticals Cancer Tubulin Inhibitors Product and Service
-
Table Agensys (Foundation Year, Company Profile and etc.)
-
Table Agensys Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Agensys Cancer Tubulin Inhibitors Product and Service
-
Table Celgene (Foundation Year, Company Profile and etc.)
-
Table Celgene Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celgene Cancer Tubulin Inhibitors Product and Service
-
Table Abraxis Biosciences (Foundation Year, Company Profile and etc.)
-
Table Abraxis Biosciences Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abraxis Biosciences Cancer Tubulin Inhibitors Product and Service
-
Table Amgen (Foundation Year, Company Profile and etc.)
-
Table Amgen Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Cancer Tubulin Inhibitors Product and Service
-
Table Tocris Bioscience (Foundation Year, Company Profile and etc.)
-
Table Tocris Bioscience Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Tocris Bioscience Cancer Tubulin Inhibitors Product and Service
-
Table Sanofi-Aventis (Foundation Year, Company Profile and etc.)
-
Table Sanofi-Aventis Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi-Aventis Cancer Tubulin Inhibitors Product and Service
-
Table Endocyte (Foundation Year, Company Profile and etc.)
-
Table Endocyte Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Endocyte Cancer Tubulin Inhibitors Product and Service
-
Table Eagle Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Eagle Pharmaceuticals Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eagle Pharmaceuticals Cancer Tubulin Inhibitors Product and Service
-
Table Pierre Fabre (Foundation Year, Company Profile and etc.)
-
Table Pierre Fabre Cancer Tubulin Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pierre Fabre Cancer Tubulin Inhibitors Product and Service
-
